Amedeo Smart

Free Medical Literature Service


 

Amedeo

Kidney Transplantation

  Free Subscription

Articles published in
Br J Clin Pharmacol
    April 2021
  1. YIN S, Wang X, Huang Z, Fan Y, et al
    Tacrolimus Variability Score Outperforms Coefficient of Variation in Predicting Clinical Outcomes of Living Kidney Transplantation.
    Br J Clin Pharmacol. 2021 Apr 25. doi: 10.1111/bcp.14876.
    >> Share

  2. RONG Y, Jun H, Kiang TKL
    Population pharmacokinetics of mycophenolic acid in paediatric patients.
    Br J Clin Pharmacol. 2021;87:1730-1757.
    >> Share

    March 2021
  3. SALLUSTIO BC, Noll BD, Hu R, Barratt DT, et al
    Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients.
    Br J Clin Pharmacol. 2021 Mar 1. doi: 10.1111/bcp.14806.
    >> Share

    December 2020
  4. JONES TE
    Problems with paper entitled The impact of tacrolimus exposure on extrarenal adverse effects in adult transplant recipients.
    Br J Clin Pharmacol. 2020;86:2536-2537.
    >> Share

  5. ROBERTSEN I, Woillard JB, Asberg A
    Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?
    Br J Clin Pharmacol. 2020;86:2535.
    >> Share

    October 2020
  6. FRANCKE MI, Hesselink DA, Li Y, Koch BCP, et al
    Monitoring the Tacrolimus Concentration in peripheral bLood mononuclear cells of Kidney Transplant Recipients.
    Br J Clin Pharmacol. 2020 Oct 6. doi: 10.1111/bcp.14585.
    >> Share

    February 2020
  7. VEENHOF H, van Boven JFM, van der Voort A, Berger SP, et al
    Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus levels with Dried Blood Spot sampling: a randomized controlled hybrid implementation trial.
    Br J Clin Pharmacol. 2020 Feb 19. doi: 10.1111/bcp.14249.
    >> Share

    January 2020
  8. KLAASEN RA, Bergan S, Bremer S, Hole K, et al
    PHARMACODYNAMIC ASSESSMENT OF MYCOPHENOLIC ACID IN RESTING AND ACTIVATED TARGET CELL POPULATION DURING THE FIRST YEAR AFTER RENAL TRANSPLANTATION.
    Br J Clin Pharmacol. 2020 Jan 11. doi: 10.1111/bcp.14218.
    >> Share

    May 2019
  9. ANUTRAKULCHAI S, Pongskul C, Kritmetapak K, Limwattananon C, et al
    Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
    Br J Clin Pharmacol. 2019 May 11. doi: 10.1111/bcp.13980.
    >> Share

    March 2019
  10. ALMARDINI R, Taybeh EO, Alsous MM, Hawwa AF, et al
    A multiple methods approach to determine adherence with prescribed mycophenolate in children with kidney transplant.
    Br J Clin Pharmacol. 2019 Mar 7. doi: 10.1111/bcp.13911.
    >> Share

    January 2019
  11. SALLUSTIO BC, Noll BD, Coller JK, Tuke J, et al
    Relationship between allograft cyclosporin concentrations and P-glycoprotein expression in the first month following renal transplantation.
    Br J Clin Pharmacol. 2019 Jan 28. doi: 10.1111/bcp.13880.
    >> Share

    December 2018
  12. ZHANG HX, Sheng CC, Liu LS, Luo B, et al
    Systematic external evaluation of published population pharmacokinetic models of mycophenolate mofetil in adult kidney transplant recipients co-administered with tacrolimus.
    Br J Clin Pharmacol. 2018 Dec 29. doi: 10.1111/bcp.13850.
    >> Share

  13. ANDREWS LM, Hesselink DA, van Schaik RHN, van Gelder T, et al
    A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
    Br J Clin Pharmacol. 2018 Dec 14. doi: 10.1111/bcp.13838.
    >> Share

    November 2018
  14. CAMPAGNE O, Mager DE, Brazeau D, Venuto RC, et al
    The Impact of Tacrolimus Exposure on Extrarenal Adverse Effects in Adult Renal Transplant Recipients.
    Br J Clin Pharmacol. 2018 Nov 10. doi: 10.1111/bcp.13811.
    >> Share

    September 2018
  15. ZWART TC, Gokoel SRM, van der Boog PJM, de Fijter JW, et al
    herapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.
    Br J Clin Pharmacol. 2018 Sep 3. doi: 10.1111/bcp.13755.
    >> Share

    July 2018
  16. MD DOM ZI, Coller JK, Carroll RP, Tuke J, et al
    Mycophenolic Acid Concentrations in Peripheral Blood Mononuclear Cells are Associated with the Incidence of Rejection in Renal Transplant Recipients.
    Br J Clin Pharmacol. 2018 Jul 2. doi: 10.1111/bcp.13704.
    >> Share

    April 2018
  17. LIN XB, Li ZW, Yan M, Zhang BK, et al
    Population Pharmacokinetics of Voriconazole and CYP2C19 Polymorphisms for Optimizing Dosing Regimens in Renal Transplant Recipients.
    Br J Clin Pharmacol. 2018 Apr 1. doi: 10.1111/bcp.13595.
    >> Share

    January 2018
  18. VAN SLOTEN TT, de Klaver PAG, van den Wall Bake AWL
    Co-administration of cyclosporine and ticagrelor may lead to a higher exposure to cyclosporine: a case report of a 49-year-old man.
    Br J Clin Pharmacol. 2018;84:208-210.
    >> Share

    September 2017
  19. MAO JJ, Jiao Z, Yun HY, Zhao CY, et al
    External Evaluation of Population Pharmacokinetic Models for Cyclosporine in Adult Renal Transplant Recipients.
    Br J Clin Pharmacol. 2017 Sep 11. doi: 10.1111/bcp.13431.
    >> Share

  20. MILLAN O, Budde K, Sommerer C, Aliart I, et al
    Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation.
    Br J Clin Pharmacol. 2017 Sep 7. doi: 10.1111/bcp.13399.
    >> Share

    July 2017
  21. BREMER S, Vethe NT, Skauby M, Kasbo M, et al
    NFAT-regulated cytokine gene expression during tacrolimus therapy early after renal transplantation.
    Br J Clin Pharmacol. 2017 Jul 7. doi: 10.1111/bcp.13367.
    >> Share

    June 2017
  22. VANHOVE T, Hasan M, Annaert P, Oswald S, et al
    Pretransplant 4beta-hydroxycholesterol does not predict tacrolimus exposure or dose requirements during the first days after kidney transplantation.
    Br J Clin Pharmacol. 2017 Jun 11. doi: 10.1111/bcp.13343.
    >> Share

  23. STORSET E, Hole K, Midtvedt K, Bergan S, et al
    Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.
    Br J Clin Pharmacol. 2017;83:1357-1358.
    >> Share

  24. VANHOVE T, Annaert P, Kuypers DRJ
    Response to: 'Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'.
    Br J Clin Pharmacol. 2017;83:1353-1356.
    >> Share

  25. STORSET E, Hole K, Midtvedt K, Bergan S, et al
    Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance.
    Br J Clin Pharmacol. 2017;83:1350-1352.
    >> Share

    April 2017
  26. KNOPS N, Herman J, van Dyck M, Ramazani Y, et al
    Tacrolimus dose requirements in paediatric renal allograft recipients are characterized by a biphasic course determined by age and bone maturation.
    Br J Clin Pharmacol. 2017;83:863-874.
    >> Share

    March 2017
  27. RIVOLI L, Vliegenthart AD, de Potter CM, van Bragt JJ, et al
    The effect of renal dysfunction and haemodialysis on circulating liver specific miR-122.
    Br J Clin Pharmacol. 2017;83:584-592.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016